Modulation of hepatic amyloid precursor protein and lipoprotein receptor-related protein 1 by chronic alcohol intake: Potential link between liver steatosis and amyloid-β.

Alzheimer’s disease alcohol amyloid precursor protein beta-amyloid lipoprotein receptor-related protein 1 liver

Journal

Frontiers in physiology
ISSN: 1664-042X
Titre abrégé: Front Physiol
Pays: Switzerland
ID NLM: 101549006

Informations de publication

Date de publication:
2022
Historique:
received: 27 04 2022
accepted: 09 08 2022
entrez: 3 10 2022
pubmed: 4 10 2022
medline: 4 10 2022
Statut: epublish

Résumé

Heavy alcohol consumption is a known risk factor for various forms of dementia and the development of Alzheimer's disease (AD). In this work, we investigated how intragastric alcohol feeding may alter the liver-to-brain axis to induce and/or promote AD pathology. Four weeks of intragastric alcohol feeding to mice, which causes significant fatty liver (steatosis) and liver injury, caused no changes in AD pathology markers in the brain [amyloid precursor protein (APP), presenilin], except for a decrease in microglial cell number in the cortex of the brain. Interestingly, the decline in microglial numbers correlated with serum alanine transaminase (ALT) levels, suggesting a potential link between liver injury and microglial loss in the brain. Intragastric alcohol feeding significantly affected two hepatic proteins important in amyloid-beta (Aβ) processing by the liver: 1) alcohol feeding downregulated lipoprotein receptor-related protein 1 (LRP1, ∼46%), the major receptor in the liver that removes Aβ from blood and peripheral organs, and 2) alcohol significantly upregulated APP (∼2-fold), a potentially important source of Aβ in the periphery and brain. The decrease in hepatic LRP1 and increase in hepatic APP likely switches the liver from being a remover or low producer of Aβ to an important source of Aβ in the periphery, which can impact the brain. The downregulation of LRP1 and upregulation of APP in the liver was observed in the first week of intragastric alcohol feeding, and also occurred in other alcohol feeding models (NIAAA binge alcohol model and intragastric alcohol feeding to rats). Modulation of hepatic LRP1 and APP does not seem alcohol-specific, as ob/ob mice with significant steatosis also had declines in LRP1 and increases in APP expression in the liver. These findings suggest that liver steatosis rather than alcohol-induced liver injury is likely responsible for regulation of hepatic LRP1 and APP. Both obesity and alcohol intake have been linked to AD and our data suggests that liver steatosis associated with these two conditions modulates hepatic LRP1 and APP to disrupt Aβ processing by the liver to promote AD.

Identifiants

pubmed: 36187787
doi: 10.3389/fphys.2022.930402
pii: 930402
pmc: PMC9520570
doi:

Types de publication

Journal Article

Langues

eng

Pagination

930402

Subventions

Organisme : NIA NIH HHS
ID : R01 AG072896
Pays : United States
Organisme : NIAAA NIH HHS
ID : R21 AA026944
Pays : United States

Informations de copyright

Copyright © 2022 Garcia, Chang, Steinberg, Arce, Yang, Van Der Eb, Abdullah, Chandrashekar, Eck, Meza, Liu, Cadenas, Cribbs, Kaplowitz, Sumbria and Han.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Front Neuroanat. 2020 Aug 13;14:52
pubmed: 32903737
EMBO J. 1988 Sep;7(9):2807-13
pubmed: 3053167
J Proteome Res. 2014 Mar 7;13(3):1731-43
pubmed: 24479691
Am J Physiol Gastrointest Liver Physiol. 2006 Jul;291(1):G1-7
pubmed: 16500922
Hepatology. 2021 Dec;74(6):3127-3145
pubmed: 34331779
Hepatology. 1985 Mar-Apr;5(2):224-32
pubmed: 3979954
J Neurochem. 2010 Dec;115(5):1077-89
pubmed: 20854368
J Neuroinflammation. 2018 May 14;15(1):141
pubmed: 29759078
Cardiovasc Res. 2007 Jun 1;74(3):526-36
pubmed: 17376415
Curr Alzheimer Res. 2016;13(12):1356-1362
pubmed: 27628432
J Biol Chem. 2003 Apr 4;278(14):11945-53
pubmed: 12551936
Brain Res Mol Brain Res. 1996 Jan;35(1-2):325-8
pubmed: 8717371
PLoS Biol. 2021 Sep 14;19(9):e3001358
pubmed: 34520451
Alcohol Clin Exp Res. 1995 Feb;19(1):110-22
pubmed: 7771636
Drug Metab Dispos. 2013 Oct;41(10):1787-96
pubmed: 23852717
Atherosclerosis. 2014 Mar;233(1):178-85
pubmed: 24529141
Proc Natl Acad Sci U S A. 2012 Feb 28;109(9):3510-5
pubmed: 22308347
Ann Neurol. 1993 Mar;33(3):258-66
pubmed: 8498809
Free Radic Biol Med. 2017 Jan;102:100-110
pubmed: 27867097
BMB Rep. 2011 Feb;44(2):135-9
pubmed: 21345314
Alcohol Clin Exp Res. 2001 May;25(5 Suppl ISBRA):104S-109S
pubmed: 11391058
Mol Metab. 2021 Mar;45:101154
pubmed: 33359401
Mol Neurobiol. 2018 Jun;55(6):5006-5018
pubmed: 28799137
Cell Metab. 2014 Jan 7;19(1):84-95
pubmed: 24411941
Eur J Med Res. 2015 Feb 11;20:15
pubmed: 25888859
J Biol Chem. 2012 Dec 7;287(50):42165-79
pubmed: 23086958
Hum Mol Genet. 2010 Apr 15;19(R1):R12-20
pubmed: 20413653
J Cell Biol. 2018 Feb 5;217(2):459-472
pubmed: 29196460
Medicine (Baltimore). 2017 Aug;96(32):e7743
pubmed: 28796060
PLoS One. 2010 Aug 16;5(8):e12147
pubmed: 20808936
Hepatology. 2010 Mar;51(3):796-805
pubmed: 20069651
Nat Commun. 2019 Aug 21;10(1):3758
pubmed: 31434879
FEBS Lett. 2018 Mar;592(6):916-927
pubmed: 29430655
J Alzheimers Dis. 2020;75(1):1-14
pubmed: 32250293
Atherosclerosis. 2010 Dec;213(2):458-68
pubmed: 20980003
Alcohol Alcohol. 2017 Mar 9;52(2):158
pubmed: 28182204
Pharm Res. 2006 Jul;23(7):1407-16
pubmed: 16779710
J Alzheimers Dis. 2012;28(1):163-71
pubmed: 21965312
J Clin Invest. 2017 Sep 1;127(9):3240-3249
pubmed: 28862638
J Hepatol. 2022 Jan;76(1):11-24
pubmed: 34555423
J Neurosci Res. 2011 Jun;89(6):808-14
pubmed: 21374699
Nat Protoc. 2013 Mar;8(3):627-37
pubmed: 23449255
J Biol Chem. 1992 Aug 25;267(24):17362-8
pubmed: 1380960
J Neuropathol Exp Neurol. 1988 Sep;47(5):516-25
pubmed: 2971785
J Hepatol. 2006 Nov;45(5):717-24
pubmed: 16879892
Nat Rev Neurol. 2021 Mar;17(3):157-172
pubmed: 33318676
J Biol Chem. 2005 May 6;280(18):17777-85
pubmed: 15749709
Brain Res Mol Brain Res. 1995 Nov;33(2):245-53
pubmed: 8750883
J Biol Chem. 2004 Oct 29;279(44):45897-908
pubmed: 15322125
Mol Neurobiol. 2017 Apr;54(3):2338-2344
pubmed: 26957302
Neurology. 2008 Sep 30;71(14):1057-64
pubmed: 18367704
J Neuroinflammation. 2016 Jan 05;13:1
pubmed: 26728181
J Neuroinflammation. 2021 Dec 31;18(1):312
pubmed: 34972522
Nat Med. 2007 Sep;13(9):1029-31
pubmed: 17694066

Auteurs

Jerome Garcia (J)

Department of Biology, University of La Verne, Verne, CA, United States.

Rudy Chang (R)

Department of Biomedical and Pharmaceutical Sciences, School of Pharmacy, Chapman University, Irvine, CA, United States.

Ross A Steinberg (RA)

School of Pharmacy and Health Sciences, Keck Graduate Institute, Claremont, CA, United States.

Aldo Arce (A)

School of Pharmacy and Health Sciences, Keck Graduate Institute, Claremont, CA, United States.

Joshua Yang (J)

Department of Biomedical and Pharmaceutical Sciences, School of Pharmacy, Chapman University, Irvine, CA, United States.

Peter Van Der Eb (P)

School of Pharmacy and Health Sciences, Keck Graduate Institute, Claremont, CA, United States.

Tamara Abdullah (T)

Department of Biomedical and Pharmaceutical Sciences, School of Pharmacy, Chapman University, Irvine, CA, United States.

Devaraj V Chandrashekar (DV)

Department of Biomedical and Pharmaceutical Sciences, School of Pharmacy, Chapman University, Irvine, CA, United States.

Sydney M Eck (SM)

School of Pharmacy and Health Sciences, Keck Graduate Institute, Claremont, CA, United States.

Pablo Meza (P)

School of Pharmacy and Health Sciences, Keck Graduate Institute, Claremont, CA, United States.

Zhang-Xu Liu (ZX)

Department of Molecular Microbiology and Immunology, USC/Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States.

Enrique Cadenas (E)

Department of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California, Los Angeles, CA, United States.

David H Cribbs (DH)

Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, Irvine, CA, United States.

Neil Kaplowitz (N)

University of Southern California Research Center for Liver Diseases and Southern California Research Center for ALPD, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States.

Rachita K Sumbria (RK)

Department of Biomedical and Pharmaceutical Sciences, School of Pharmacy, Chapman University, Irvine, CA, United States.
Department of Neurology, University of California, Irvine, Irvine, CA, United States.

Derick Han (D)

School of Pharmacy and Health Sciences, Keck Graduate Institute, Claremont, CA, United States.

Classifications MeSH